WAVE Life Sciences Ltd. (NASDAQ:WVE) shares rose 2% during trading on Monday . The stock traded as high as $24.95 and last traded at $22.80. Approximately 61,800 shares traded hands during trading, a decline of 35% from the average daily volume of 94,884 shares. The stock had previously closed at $22.35.

WVE has been the topic of several research reports. Zacks Investment Research downgraded WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Jefferies Group LLC restated a “buy” rating and set a $40.00 price objective (down from $42.00) on shares of WAVE Life Sciences in a report on Thursday, August 10th. Mizuho set a $34.00 price objective on WAVE Life Sciences and gave the stock a “buy” rating in a report on Friday, August 18th. Finally, BidaskClub upgraded WAVE Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $38.75.

The company has a debt-to-equity ratio of 0.01, a current ratio of 11.50 and a quick ratio of 11.50.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.97) by $0.03. WAVE Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.77 million. research analysts predict that WAVE Life Sciences Ltd. will post -3.75 earnings per share for the current fiscal year.

In other news, Director Masaharu Tanaka sold 20,747 shares of WAVE Life Sciences stock in a transaction on Monday, September 18th. The stock was sold at an average price of $24.21, for a total value of $502,284.87. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 53.00% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Redmile Group LLC grew its stake in WAVE Life Sciences by 75.0% during the 2nd quarter. Redmile Group LLC now owns 2,224,407 shares of the company’s stock worth $41,374,000 after buying an additional 953,310 shares during the last quarter. Vanguard Group Inc. grew its stake in WAVE Life Sciences by 40.3% during the 2nd quarter. Vanguard Group Inc. now owns 215,691 shares of the company’s stock worth $4,012,000 after buying an additional 61,910 shares during the last quarter. Northern Trust Corp grew its stake in WAVE Life Sciences by 66.3% during the 2nd quarter. Northern Trust Corp now owns 165,794 shares of the company’s stock worth $3,085,000 after buying an additional 66,120 shares during the last quarter. State Street Corp grew its stake in WAVE Life Sciences by 26.6% during the 2nd quarter. State Street Corp now owns 151,241 shares of the company’s stock worth $2,815,000 after buying an additional 31,743 shares during the last quarter. Finally, Sabby Management LLC purchased a new position in WAVE Life Sciences during the 2nd quarter worth $2,636,000. Hedge funds and other institutional investors own 69.53% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/13/wave-life-sciences-ltd-wve-stock-price-up-2.html.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.